StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Up 1.3 %
TTNP stock opened at $3.23 on Friday. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80. The business has a 50-day moving average of $3.72 and a 200-day moving average of $4.95.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- How Investors Can Find the Best Cheap Dividend Stocks
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- What Are Dividends? Buy the Best Dividend Stocks
- Nebius Group: The Rising Star in AI Infrastructure
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
